Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size, Status and Forecast 2024-2031

Report ID: 918293 | Published Date: Feb 2026 | No. of Page: 125 | Base Year: 2025 | Rating: 4.6 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%)

Impact of U.S Tarrifs Analyzed 2025 

1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 Icotinib
        1.2.3 Gefitinib
        1.2.4 Erlotinib
        1.2.5 Afatinib
        1.2.6 Osimertinib
        1.2.7 Brigatinib
        1.2.8 Other
    1.3 Market by Application
        1.3.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Squamous Cell Carcinoma of NSCLC
        1.3.3 Adenocarcinoma of NSCLC
        1.3.4 Large Cell Carcinoma of NSCLC
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Perspective (2016-2027)
    2.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Growth Trends by Regions
        2.2.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Historic Market Share by Regions (2016-2021)
        2.2.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Regions (2022-2027)
    2.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Industry Dynamic
        2.3.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Trends
        2.3.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Drivers
        2.3.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Challenges
        2.3.4 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC Players by Revenue
        3.1.1 Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC Players by Revenue (2016-2021)
        3.1.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Players (2016-2021)
    3.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue
    3.4 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Concentration Ratio
        3.4.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue in 2020
    3.5 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players Head office and Area Served
    3.6 Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Product Solution and Service
    3.7 Date of Enter into Targeted Drug EGFR RTK Inhibitors for NSCLC Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Targeted Drug EGFR RTK Inhibitors for NSCLC Breakdown Data by Type
    4.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Historic Market Size by Type (2016-2021)
    4.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Type (2022-2027)

5 Targeted Drug EGFR RTK Inhibitors for NSCLC Breakdown Data by Application
    5.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Historic Market Size by Application (2016-2021)
    5.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2016-2027)
    6.2 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type
        6.2.1 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2016-2021)
        6.2.2 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2022-2027)
        6.2.3 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2016-2027)
    6.3 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application
        6.3.1 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2016-2021)
        6.3.2 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2022-2027)
        6.3.3 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2016-2027)
    6.4 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country
        6.4.1 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2016-2021)
        6.4.2 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2016-2027)
    7.2 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type
        7.2.1 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2016-2021)
        7.2.2 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2022-2027)
        7.2.3 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2016-2027)
    7.3 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application
        7.3.1 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2016-2021)
        7.3.2 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2022-2027)
        7.3.3 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2016-2027)
    7.4 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country
        7.4.1 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2016-2021)
        7.4.2 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2016-2027)
    8.2 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type
        8.2.1 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2016-2027)
    8.3 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application
        8.3.1 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2016-2027)
    8.4 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region
        8.4.1 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2016-2027)
    9.2 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type
        9.2.1 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2016-2021)
        9.2.2 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2022-2027)
        9.2.3 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2016-2027)
    9.3 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application
        9.3.1 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2016-2021)
        9.3.2 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2022-2027)
        9.3.3 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2016-2027)
    9.4 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country
        9.4.1 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2016-2021)
        9.4.2 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2016-2027)
    10.2 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type
        10.2.1 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2016-2027)
    10.3 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application
        10.3.1 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2016-2027)
    10.4 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country
        10.4.1 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 Beta Pharma
        11.1.1 Beta Pharma Company Details
        11.1.2 Beta Pharma Business Overview
        11.1.3 Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.1.4 Beta Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
        11.1.5 Beta Pharma Recent Development
    11.2 AstraZeneca
        11.2.1 AstraZeneca Company Details
        11.2.2 AstraZeneca Business Overview
        11.2.3 AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.2.4 AstraZeneca Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
        11.2.5 AstraZeneca Recent Development
    11.3 Natco Pharma
        11.3.1 Natco Pharma Company Details
        11.3.2 Natco Pharma Business Overview
        11.3.3 Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.3.4 Natco Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
        11.3.5 Natco Pharma Recent Development
    11.4 Qilu Pharmaceutical
        11.4.1 Qilu Pharmaceutical Company Details
        11.4.2 Qilu Pharmaceutical Business Overview
        11.4.3 Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.4.4 Qilu Pharmaceutical Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
        11.4.5 Qilu Pharmaceutical Recent Development
    11.5 Genentech (Roche Group)
        11.5.1 Genentech (Roche Group) Company Details
        11.5.2 Genentech (Roche Group) Business Overview
        11.5.3 Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.5.4 Genentech (Roche Group) Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
        11.5.5 Genentech (Roche Group) Recent Development
    11.6 Mylan
        11.6.1 Mylan Company Details
        11.6.2 Mylan Business Overview
        11.6.3 Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.6.4 Mylan Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
        11.6.5 Mylan Recent Development
    11.7 Teva
        11.7.1 Teva Company Details
        11.7.2 Teva Business Overview
        11.7.3 Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.7.4 Teva Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
        11.7.5 Teva Recent Development
    11.8 OSI Pharmaceuticals
        11.8.1 OSI Pharmaceuticals Company Details
        11.8.2 OSI Pharmaceuticals Business Overview
        11.8.3 OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.8.4 OSI Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
        11.8.5 OSI Pharmaceuticals Recent Development
    11.9 Glenmark Pharmaceuticals
        11.9.1 Glenmark Pharmaceuticals Company Details
        11.9.2 Glenmark Pharmaceuticals Business Overview
        11.9.3 Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.9.4 Glenmark Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
        11.9.5 Glenmark Pharmaceuticals Recent Development
    11.10 Beacon Pharmaceuticals
        11.10.1 Beacon Pharmaceuticals Company Details
        11.10.2 Beacon Pharmaceuticals Business Overview
        11.10.3 Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.10.4 Beacon Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
        11.10.5 Beacon Pharmaceuticals Recent Development
    11.11 Boehringer Ingelheim
        11.11.1 Boehringer Ingelheim Company Details
        11.11.2 Boehringer Ingelheim Business Overview
        11.11.3 Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.11.4 Boehringer Ingelheim Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
        11.11.5 Boehringer Ingelheim Recent Development
    11.12 Pfizer
        11.12.1 Pfizer Company Details
        11.12.2 Pfizer Business Overview
        11.12.3 Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.12.4 Pfizer Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
        11.12.5 Pfizer Recent Development
    11.13 ARIAD Pharmaceuticals (Takeda)
        11.13.1 ARIAD Pharmaceuticals (Takeda) Company Details
        11.13.2 ARIAD Pharmaceuticals (Takeda) Business Overview
        11.13.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.13.4 ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
        11.13.5 ARIAD Pharmaceuticals (Takeda) Recent Development
    11.14 Genvio Pharma Limited
        11.14.1 Genvio Pharma Limited Company Details
        11.14.2 Genvio Pharma Limited Business Overview
        11.14.3 Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.14.4 Genvio Pharma Limited Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
        11.14.5 Genvio Pharma Limited Recent Development
    11.15 Drug International Limted
        11.15.1 Drug International Limted Company Details
        11.15.2 Drug International Limted Business Overview
        11.15.3 Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.15.4 Drug International Limted Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
        11.15.5 Drug International Limted Recent Development
    11.16 Everest Pharmaceuticals
        11.16.1 Everest Pharmaceuticals Company Details
        11.16.2 Everest Pharmaceuticals Business Overview
        11.16.3 Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.16.4 Everest Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
        11.16.5 Everest Pharmaceuticals Recent Development
    11.17 Incepta Pharmaceuticals Limited
        11.17.1 Incepta Pharmaceuticals Limited Company Details
        11.17.2 Incepta Pharmaceuticals Limited Business Overview
        11.17.3 Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.17.4 Incepta Pharmaceuticals Limited Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
        11.17.5 Incepta Pharmaceuticals Limited Recent Development
    11.18 Cipla Pharma
        11.18.1 Cipla Pharma Company Details
        11.18.2 Cipla Pharma Business Overview
        11.18.3 Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.18.4 Cipla Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
        11.18.5 Cipla Pharma Recent Development
    11.18 Dr Reddy's Laboratories
        11.25.1 Dr Reddy's Laboratories Company Details
        11.25.2 Dr Reddy's Laboratories Business Overview
        11.25.3 Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.25.4 Dr Reddy's Laboratories Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
        11.25.5 Dr Reddy's Laboratories Recent Development
    11.20 Zydus Cadila
        11.20.1 Zydus Cadila Company Details
        11.20.2 Zydus Cadila Business Overview
        11.20.3 Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.20.4 Zydus Cadila Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
        11.20.5 Zydus Cadila Recent Development
    11.21 Hetero Drugs
        11.21.1 Hetero Drugs Company Details
        11.21.2 Hetero Drugs Business Overview
        11.21.3 Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.21.4 Hetero Drugs Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
        11.21.5 Hetero Drugs Recent Development
    11.22 Intas Pharmaceuticals
        11.22.1 Intas Pharmaceuticals Company Details
        11.22.2 Intas Pharmaceuticals Business Overview
        11.22.3 Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.22.4 Intas Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
        11.22.5 Intas Pharmaceuticals Recent Development
    11.23 Alkem Laboratories
        11.23.1 Alkem Laboratories Company Details
        11.23.2 Alkem Laboratories Business Overview
        11.23.3 Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.23.4 Alkem Laboratories Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
        11.23.5 Alkem Laboratories Recent Development
    11.24 RPG Life Sciences
        11.24.1 RPG Life Sciences Company Details
        11.24.2 RPG Life Sciences Business Overview
        11.24.3 RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.24.4 RPG Life Sciences Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
        11.24.5 RPG Life Sciences Recent Development
    11.25 Fresenius Kabi India
        11.25.1 Fresenius Kabi India Company Details
        11.25.2 Fresenius Kabi India Business Overview
        11.25.3 Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.25.4 Fresenius Kabi India Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
        11.25.5 Fresenius Kabi India Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Icotinib
    Table 3. Key Players of Gefitinib
    Table 4. Key Players of Erlotinib
    Table 5. Key Players of Afatinib
    Table 6. Key Players of Osimertinib
    Table 7. Key Players of Brigatinib
    Table 8. Key Players of Other
    Table 9. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 10. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 11. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Regions (2016-2021) & (US$ Million)
    Table 12. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Regions (2016-2021)
    Table 13. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 14. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Regions (2022-2027)
    Table 15. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Trends
    Table 16. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Drivers
    Table 17. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Challenges
    Table 18. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Restraints
    Table 19. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Players (2016-2021) & (US$ Million)
    Table 20. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Players (2016-2021)
    Table 21. Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC as of 2020)
    Table 22. Ranking of Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC Companies by Revenue (US$ Million) in 2020
    Table 23. Global 5 Largest Players Market Share by Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (CR5 and HHI) & (2016-2021)
    Table 24. Key Players Headquarters and Area Served
    Table 25. Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Product Solution and Service
    Table 26. Date of Enter into Targeted Drug EGFR RTK Inhibitors for NSCLC Market
    Table 27. Mergers & Acquisitions, Expansion Plans
    Table 28. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2016-2021) (US$ Million)
    Table 29. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Type (2016-2021)
    Table 30. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 31. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 32. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Share by Application (2016-2021) & (US$ Million)
    Table 33. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Application (2016-2021)
    Table 34. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 35. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 36. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2016-2021) (US$ Million)
    Table 37. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2022-2027) & (US$ Million)
    Table 38. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2016-2021) (US$ Million)
    Table 39. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2022-2027) & (US$ Million)
    Table 40. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2016-2021) & (US$ Million) 
    Table 41. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2022-2027) & (US$ Million) 
    Table 42. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2016-2021) (US$ Million)
    Table 43. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2022-2027) & (US$ Million)
    Table 44. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2016-2021) (US$ Million)
    Table 45. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2022-2027) & (US$ Million)
    Table 46. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2016-2021) & (US$ Million) 
    Table 47. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2022-2027) & (US$ Million) 
    Table 48. Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2016-2021) (US$ Million)
    Table 49. Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2022-2027) & (US$ Million)
    Table 50. Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2016-2021) (US$ Million)
    Table 51. Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2022-2027) & (US$ Million)
    Table 52. Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (2016-2021) & (US$ Million) 
    Table 53. Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (2022-2027) & (US$ Million) 
    Table 54. Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2016-2021) (US$ Million)
    Table 55. Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2022-2027) & (US$ Million)
    Table 56. Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2016-2021) (US$ Million)
    Table 57. Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2022-2027) & (US$ Million)
    Table 58. Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2016-2021) & (US$ Million) 
    Table 59. Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2022-2027) & (US$ Million) 
    Table 60. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2016-2021) (US$ Million)
    Table 61. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2022-2027) & (US$ Million)
    Table 62. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2016-2021) (US$ Million)
    Table 63. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2022-2027) & (US$ Million)
    Table 64. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2016-2021) & (US$ Million) 
    Table 65. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2022-2027) & (US$ Million) 
    Table 66. Beta Pharma Company Details
    Table 67. Beta Pharma Business Overview
    Table 68. Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 69. Beta Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 70. Beta Pharma Recent Development
    Table 71. AstraZeneca Company Details
    Table 72. AstraZeneca Business Overview
    Table 73. AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 74. AstraZeneca Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 75. AstraZeneca Recent Development
    Table 76. Natco Pharma Company Details
    Table 77. Natco Pharma Business Overview
    Table 78. Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 79. Natco Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 80. Natco Pharma Recent Development
    Table 81. Qilu Pharmaceutical Company Details
    Table 82. Qilu Pharmaceutical Business Overview
    Table 83. Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 84. Qilu Pharmaceutical Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 85. Qilu Pharmaceutical Recent Development
    Table 86. Genentech (Roche Group) Company Details
    Table 87. Genentech (Roche Group) Business Overview
    Table 88. Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 89. Genentech (Roche Group) Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 90. Genentech (Roche Group) Recent Development
    Table 91. Mylan Company Details
    Table 92. Mylan Business Overview
    Table 93. Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 94. Mylan Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 95. Mylan Recent Development
    Table 96. Teva Company Details
    Table 97. Teva Business Overview
    Table 98. Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 99. Teva Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 100. Teva Recent Development
    Table 101. OSI Pharmaceuticals Company Details
    Table 102. OSI Pharmaceuticals Business Overview
    Table 103. OSI Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 104. OSI Pharmaceuticals Recent Development
    Table 105. Glenmark Pharmaceuticals Company Details
    Table 106. Glenmark Pharmaceuticals Business Overview
    Table 107. Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 108. Glenmark Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 109. Glenmark Pharmaceuticals Recent Development
    Table 110. Beacon Pharmaceuticals Company Details
    Table 111. Beacon Pharmaceuticals Business Overview
    Table 112. Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 113. Beacon Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 114. Beacon Pharmaceuticals Recent Development
    Table 115. Boehringer Ingelheim Company Details
    Table 116. Boehringer Ingelheim Business Overview
    Table 117. Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 118. Boehringer Ingelheim Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 119. Boehringer Ingelheim Recent Development
    Table 120. Pfizer Company Details
    Table 121. Pfizer Business Overview
    Table 122. Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 123. Pfizer Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 124. Pfizer Recent Development
    Table 125. ARIAD Pharmaceuticals (Takeda) Company Details
    Table 126. ARIAD Pharmaceuticals (Takeda) Business Overview
    Table 127. ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 128. ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 129. ARIAD Pharmaceuticals (Takeda) Recent Development
    Table 130. Genvio Pharma Limited Company Details
    Table 131. Genvio Pharma Limited Business Overview
    Table 132. Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 133. Genvio Pharma Limited Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 134. Genvio Pharma Limited Recent Development
    Table 135. Drug International Limted Company Details
    Table 136. Drug International Limted Business Overview
    Table 137. Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 138. Drug International Limted Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 139. Drug International Limted Recent Development
    Table 140. Everest Pharmaceuticals Company Details
    Table 141. Everest Pharmaceuticals Business Overview
    Table 142. Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 143. Everest Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 144. Everest Pharmaceuticals Recent Development
    Table 145. Incepta Pharmaceuticals Limited Company Details
    Table 146. Incepta Pharmaceuticals Limited Business Overview
    Table 147. Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 148. Incepta Pharmaceuticals Limited Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 149. Incepta Pharmaceuticals Limited Recent Development
    Table 150. Cipla Pharma Company Details
    Table 151. Cipla Pharma Business Overview
    Table 152. Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 153. Cipla Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 154. Cipla Pharma Recent Development
    Table 155. Dr Reddy's Laboratories Company Details
    Table 156. Dr Reddy's Laboratories Business Overview
    Table 157. Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 158. Dr Reddy's Laboratories Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 159. Dr Reddy's Laboratories Recent Development
    Table 160. Zydus Cadila Company Details
    Table 161. Zydus Cadila Business Overview
    Table 162. Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 163. Zydus Cadila Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 164. Zydus Cadila Recent Development
    Table 165. Hetero Drugs Company Details
    Table 166. Hetero Drugs Business Overview
    Table 167. Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 168. Hetero Drugs Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 169. Hetero Drugs Recent Development
    Table 170. Intas Pharmaceuticals Company Details
    Table 171. Intas Pharmaceuticals Business Overview
    Table 172. Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 173. Intas Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 174. Intas Pharmaceuticals Recent Development
    Table 175. Alkem Laboratories Company Details
    Table 176. Alkem Laboratories Business Overview
    Table 177. Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 178. Alkem Laboratories Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 179. Alkem Laboratories Recent Development
    Table 180. RPG Life Sciences Company Details
    Table 181. RPG Life Sciences Business Overview
    Table 182. RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLCProduct
    Table 183. RPG Life Sciences Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 184. RPG Life Sciences Recent Development
    Table 185. Fresenius Kabi India Company Details
    Table 186. Fresenius Kabi India Business Overview
    Table 187. Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 188. Fresenius Kabi India Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 189. Fresenius Kabi India Recent Development
    Table 190. Research Programs/Design for This Report
    Table 191. Key Data Information from Secondary Sources
    Table 192. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type: 2020 VS 2027
    Figure 2. Icotinib Features
    Figure 3. Gefitinib Features
    Figure 4. Erlotinib Features
    Figure 5. Afatinib Features
    Figure 6. Osimertinib Features
    Figure 7. Brigatinib Features
    Figure 8. Other Features
    Figure 9. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application: 2020 VS 2027
    Figure 10. Squamous Cell Carcinoma of NSCLC Case Studies
    Figure 11. Adenocarcinoma of NSCLC Case Studies
    Figure 12. Large Cell Carcinoma of NSCLC Case Studies
    Figure 13. Targeted Drug EGFR RTK Inhibitors for NSCLC Report Years Considered
    Figure 14. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 15. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 16. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Regions: 2020 VS 2027
    Figure 17. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Regions (2022-2027)
    Figure 18. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Players in 2020
    Figure 19. Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC as of 2020
    Figure 20. The Top 10 and 5 Players Market Share by Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue in 2020
    Figure 21. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Type (2016-2021)
    Figure 22. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Type (2022-2027)
    Figure 23. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 24. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2016-2027)
    Figure 25. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2016-2027)
    Figure 26. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Country (2016-2027)
    Figure 27. United States Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 28. Canada Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 29. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 30. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2016-2027)
    Figure 31. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2016-2027)
    Figure 32. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Country (2016-2027)
    Figure 33. Germany Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. France Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. U.K. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 36. Italy Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 37. Russia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 38. Nordic Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 39. Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 40. Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2016-2027)
    Figure 41. Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2016-2027)
    Figure 42. Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Region (2016-2027)
    Figure 43. China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. South Korea Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 46. Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 47. India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 48. Australia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 49. Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 50. Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2016-2027)
    Figure 51. Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2016-2027)
    Figure 52. Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Country (2016-2027)
    Figure 53. Mexico Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 54. Brazil Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 55. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 56. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2016-2027)
    Figure 57. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2016-2027)
    Figure 58. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Country (2016-2027)
    Figure 59. Turkey Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 60. Saudi Arabia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 61. UAE Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 62. Beta Pharma Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
    Figure 63. AstraZeneca Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
    Figure 64. Natco Pharma Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
    Figure 65. Qilu Pharmaceutical Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
    Figure 66. Genentech (Roche Group) Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
    Figure 67. Mylan Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
    Figure 68. Teva Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
    Figure 69. OSI Pharmaceuticals Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
    Figure 70. Glenmark Pharmaceuticals Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
    Figure 71. Beacon Pharmaceuticals Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
    Figure 72. Boehringer Ingelheim Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
    Figure 73. Pfizer Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
    Figure 74. ARIAD Pharmaceuticals (Takeda) Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
    Figure 75. Genvio Pharma Limited Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
    Figure 76. Drug International Limted Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
    Figure 77. Everest Pharmaceuticals Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
    Figure 78. Incepta Pharmaceuticals Limited Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
    Figure 79. Cipla Pharma Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
    Figure 80. Dr Reddy's Laboratories Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
    Figure 81. Zydus Cadila Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
    Figure 82. Hetero Drugs Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
    Figure 83. Intas Pharmaceuticals Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
    Figure 84. Alkem Laboratories Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
    Figure 85. RPG Life Sciences Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
    Figure 86. Fresenius Kabi India Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2016-2021)
    Figure 87. Bottom-up and Top-down Approaches for This Report
    Figure 88. Data Triangulation
    Figure 89. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Beta Pharma
AstraZeneca
Natco Pharma
Qilu Pharmaceutical
Genentech (Roche Group)
Mylan
Teva
OSI Pharmaceuticals
Glenmark Pharmaceuticals
Beacon Pharmaceuticals
Boehringer Ingelheim
Pfizer
ARIAD Pharmaceuticals (Takeda)
Genvio Pharma Limited
Drug International Limted
Everest Pharmaceuticals
Incepta Pharmaceuticals Limited
Cipla Pharma
Dr Reddy's Laboratories
Zydus Cadila
Hetero Drugs
Intas Pharmaceuticals
Alkem Laboratories
RPG Life Sciences
Fresenius Kabi India
Frequently Asked Questions
Targeted Drug EGFR RTK Inhibitors for NSCLC report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Targeted Drug EGFR RTK Inhibitors for NSCLC report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Targeted Drug EGFR RTK Inhibitors for NSCLC report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Melphalan

Market Analysis and Insights: Global Melphalan Market
The global Melphalan market s ... Read More